CANCER AND LEUKEMIA GROUP B

癌症和白血病 B 组

• 批准号: 3555905
• 负责人: RICHARD T SILVER
• 金额: $ 21.48万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 1979
• 资助国家: 美国
• 起止时间: 1979-04-01 至 1993-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3555905
• 关键词: 6 thioguanine; 6 thiopurine; Hodgkin's disease; acute leukemia; acute lymphocytic leukemia; asparaginase; breast neoplasms; cancer information system; cancer rehabilitation mental health service; carmustine; cooperative study; cyclophosphamide; cytogenetics; cytosine arabinoside; dacarbazine; data collection methodology /evaluation; daunorubicin; drug metabolism; fluorouracil; human subject; human therapy evaluation; lymphoma; mannitol; melphalan; methotrexate; myelogenous leukemia; neoplasm /cancer chemotherapy; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer remission /regression; neoplasm /cancer surgery; oncology nursing; pediatric neoplasm /cancer; prednisone; radiation therapy dosage; vincristine

This is a renewal application for continuing research in clinical cancer as a member of CALGB. The New York Hospital - Cornell Medical Center together with North Shore University Hospital and affiliated institutions remain a major contributor to the scientific, clinical and administrative activities of CALGB. Our multidisciplinary growth is reflected in our clinical activities (our group is now the leading contributor to CALGB studies) and our participation in CALGB affairs. Leadership activities are reflected in our administrative and scientific contributions to CALGB, our multidisciplinary growth, and in our pilot and phase II programs. Our aims are to participate in a cooperative approach in the design and conduct of therapeutic trials in cancer. In this context we will (1) determine the effect, extent and duration of remission and other responses to treatment of the diseases of concern to CALGB, (2) study the natural history, immunologic aspects, cytogenetics, and molecular biology of the diseases investigated by CALGB, (3) participate in pilot, phase II and multidisciplinary trials of CALGB, (4) continue the high level of patient accrual and data collection of the recent grant years, (5) continue our vigorous participation in Group activities as it pertains to Group science and Group administration.

这是用于继续研究临床研究的续签应用 癌症是CALGB的成员。 纽约医院 - 康奈尔 医疗中心与北岸大学医院一起 附属机构仍然是 CALB的科学，临床和行政活动。 我们的 多学科增长反映在我们的临床活动中（我们的 小组现在是Calgb研究的主要贡献者）和我们的 参与CALGB事务。 领导活动是 反映在我们的行政和科学贡献中 Calgb，我们的多学科增长以及我们的飞行员和II期 程序。 我们的目标是参加合作的方法 癌症治疗试验的设计和行为。 在这种情况下 我们将（1）确定缓解的效果，程度和持续时间 以及其他对治疗关注疾病的治疗的反应 Calgb，（2）研究自然史，免疫学方面， 研究的疾病的细胞遗传学和分子生物学 calgb，（3）参与飞行员，第二阶段和多学科 CALB的试验，（4）继续高水平的患者应计和 最近赠款年的数据收集，（5）继续我们的 与小组有关 科学与小组管理。